Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brazil, Mexico Taking Divergent Paths On Regulatory Reform

Executive Summary

Anvisa is in the process of trying to reduce some of its red tape, but the excessive bureaucracy at COFEPRIS is likely to remain in place for the foreseeable future.

You may also be interested in...

Brazil Tightens Outsourcing Restrictions Just Months After Easing Them

ANVISA's new resolution requires that companies importing finished drug products have their own quality control laboratory and warehouse.

Brazil's Backlog Is Nearly Clear, But Convergence Still A Work In Progress

Drug application backlog has been distraction for agency and prevents focus on other projects, says ANVISA General Manager of Drugs Raphael Sanches Pereira.

Latin America Regulatory Round-Up: A Red Tape Reduction In Brazil, Mexico

A recap of the latest Rx regulatory developments this summer (or winter) from Latin America regulators.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts